Slide 1: November 2017
November 2017 1 © 2017 Glaukos Corporation 1
Slide 2: Disclaimer
Disclaimer All statements other than statements of historical facts included in this presentation approval processes as we develop additional products and penetrate foreign that address activities, events or developments that we expect, believe or anticipate markets; the impact of any product liabil
Slide 3: Glaukos is Transforming Glaucoma Therapy
Glaukos is Transforming Glaucoma Therapy OUR MISSION To pioneer and lead the global glaucoma market with micro-scale injectable therapies that advance the standard-of-care and enrich the lives and treatment alternatives for glaucoma patients worldwide. OUR STRATEGY Grow Deliver Extend Transition US
Slide 4: Key Numbers
Key Numbers $5b 8.2m 300k 15 200 4 >$5 billion 8.2 million est. 300,000+ iStents 15 countries 200+ issued, 4 new Glaukos global US OHT/POAG implanted with direct licensed or products being glaucoma diagnosed & globally Glaukos sales pending Glaukos evaluated by market served treated eyes operations
Slide 5: Demonstrated Financial Performance
Demonstrated Financial Performance Total Net Sales (in millions) 86% $45 $40 $35 $30 Gross Margin* $25 $20 $15 $10 $5 $0 Q1 2013 Q2 2013 Q3 2013 Q4 2013 Q1 2014 Q2 2014 Q3 2014 Q4 2014 Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Q2 2016 Q3 2016 Q4 2016 Q1 2017 Q2 2017 Q3 2017 $109M Cash & Short-Term Equ
Slide 6: Open-Angle Glaucoma
Open-Angle Glaucoma Disease is chronic, progressive, irreversible and largely asymptomatic Typically associated with elevated intraocular pressure (IOP) Elevated IOP causes optic nerve damage and leads to vision loss NORMAL VISION Reducing IOP is only proven treatment WITH GLAUCOMA 6 © 2017 Glaukos
Slide 7: Our Solutions Portfolio
MIGS AND BEYON D Our Solutions Portfolio 7 © 2017 Glaukos Corporation
Slide 8: Current OAG Treatment Algorithm
Current OAG Treatment Algorithm Ocular Hypertension IOP is measured in millimeters of mercury (mm Hg). IOP of 21-30 mm Hg Normal IOP in healthy eyes ranges from 10-21 mm Hg. 1 Target IOP Treatment 20% ↓ from baseline; 0-1 med ≤ 18 mm Hg Open-Angle Refractory OAG 5 Glaucoma 2 Mild OAG Uncontrolled IO
Slide 9: Portfolio of Micro-Scale Injectable Therapy
Portfolio of Micro-Scale Injectable Therapy OCULAR HYPERTENSION Injectable drug delivery implant; sustained drug therapy for extended periods REFRACTORY Envision use alone or in combination with other MIGS devices OAG MILD Progression ADVANCED MODERATE OCULAR MILD MODERATE ADVANCED REFRACTORY HYPERT
Slide 10: Portfolio of Micro-Scale Injectable Therapy: Estimated US Commercialization
Portfolio of Micro-Scale Injectable Therapy: Estimated US Commercialization OCULAR HYPERTENSION 2022-23 REFRACTORY OAG MILD Progression ADVANCED MODERATE OCULAR MILD MODERATE ADVANCED REFRACTORY HYPERTENSION Addressing full range of 2020-21 glaucoma disease states and progression 2020-21 2H 2018 201
Slide 11: iDose Travoprost: First-of-a-Kind Intraocular Drug Delivery Device
iDose Travoprost: First-of-a-Kind Intraocular Drug Delivery Device Retaining OCULAR Cap HYPERTENSION Elution Membrane REFRACTORY Drug Reservoir OAG MILD Progression Titanium implant (1.8 mm x 0.5 mm) designed for continuous drug delivery directly into anterior ADVANCED MODERATE chamber Filled with p
Slide 12: iDose Travoprost US Phase II: Preliminary Efficacy Results
iDose Travoprost US Phase II: Preliminary Efficacy Results Average IOP Reductions through Month 9* Average IOP reductions through 9 10.0 9.5 months post-op 9.0 37% 8.7 8.7 8.5 8.4 8.3 8.2 8.0 8.0 7.9 ranging from 7.9 to 9.5 8.0 35% 7.6 34% 33% 7.5 33% 7.6 33% 7.5 32% 7.6 32% 32% 32% mmHg in the impl
Slide 13: iDose Travoprost Procedure
iDose Travoprost Procedure iDose is not approved by the FDA. 13 © 2017 Glaukos Corporation
Slide 14: iDose Travoprost Exchange (Removal) Procedure
iDose Travoprost Exchange (Removal) Procedure iDose is not approved by the FDA. 14 © 2017 Glaukos Corporation
Slide 15: Combination-Cataract Therapy for Mild to Moderate OAG
Combination-Cataract Therapy for Mild to Moderate OAG OCULAR HYPERTENSION REFRACTORY OAG FDA approved in 2012; Two heparin-coated titanium 4 mm implant, curved to follow MILD Progression flagship MIGS device trabecular bypass stents preloaded ocular anatomy into auto injection system Heparin-coated
Slide 16: Real-World Clinical Experience of Single Stent with Cataract Surgery
Real-World Clinical Experience of Single Stent with Cataract Surgery 42% 56% Remained Reduction in 19.4 medication free mean # of 20 24 meds Mean IOP mm Hg Mean IOP mm Hg 17.4 19.3 16.5 16.3 20 16.1 15.9 16.1 16 16.4 16.4 16.3 15.7 15.2 16 12 12 Preop Year 1 Year 2 Year 3 Year 4 Year 5 Final Preop 1
Slide 17: Clinical Performance of iStents with Cataract Surgery
Clinical Performance of 2 iStents with Cataract Surgery All subjects had IOP not well 2 iStents + Cataract controlled on medication or Comparative Case Series (n=28) well controlled with substantial (≥ 3) medication 6 20 burden 5 17.3 64% Stent implantation conducted 16 Reduction in 13.4 13.3 13.5 1
Slide 18: Facile, Click-and-Release 2-Stent Procedure
Facile, Click-and-Release 2-Stent Procedure iStent SA is not approved by the FDA. 18 © 2017 Glaukos Corporation
Slide 19: Standalone 2-Stent Therapy for Mild to Moderate OAG
Standalone 2-Stent Therapy for Mild to Moderate OAG OCULAR HYPERTENSION REFRACTORY OAG MILD Progression 2 Standalone Stents Two heparin-coated titanium stents, preloaded into auto injection system 26 24.4 ADVANCED MODERATE Tapered insertion sleeve yields smooth insertion during closed-chamber 22 19.
Slide 20: MIGS Solution for Advanced and Refractory OAG
MIGS Solution for Advanced and Refractory OAG OCULAR HYPERTENSION REFRACTORY OAG Titratable Stent Therapy MILD Progression Three heparin-coated trabecular bypass 1 Stent stents, identical to iStent SA 26 2 Stent ADVANCED MODERATE Enhanced insertion system provides 22 3 Stent Mean IOP mm Hg unlimited
Slide 21: MIGS Solution for Advanced and Refractory OAG
MIGS Solution for Advanced and Refractory OAG iStent infinite is not approved by the FDA. 21 © 2017 Glaukos Corporation
Slide 22: Competitive Surgical Landscape
Competitive Surgical Landscape Mild to Refractory Moderate Alcon CyPass Allergan XEN • 6.35 mm polyimide shunt • 6 mm collagen shunt implanted implanted ab interno into ab interno into subconjunctival suprachoroidal space space • Approved by FDA in 2016 for • Creates bleb; requires use of combo-cata
Slide 23: Delivering Novel Surgical & Pharmaceutical Glaucoma Therapy
PLATFOR M D EVELOPMEN T Delivering Novel Surgical & Pharmaceutical Glaucoma Therapy 23 © 2017 Glaukos Corporation
Slide 24: Platform Pillars of Hybrid Pharma/Device Leader
Platform Pillars of Hybrid Pharma/Device Leader Restoring natural, IOP diagnostics and physiological outflow management Portfolio of micro-scale flow Goal to provide micro-scale in vivo devices for full range of glaucoma MEMS tools for monitoring and managing severity and progression Biosensors IOP
Slide 25: Expanding Our Annual Market Opportunity 7x+
Expanding Our Annual Market Opportunity 7x+ OHT/POAG prevalence: US Annual Opportunity* ~18M eyes (eyes) ~ 4.3M 8.2M eyes diagnosed and treated Growing 3.5% annually 33% of standalone ~ 1.3M OHT/POAG population is pseudophakic ~ 1.1M Combination therapy drives more opportunity for ~ 0.6M Glaukos por
Slide 26: Glaukos: Key Takeaways
Glaukos: Key Takeaways Delivering novel • Validating the narrative of sustained glaucoma drug surgical and delivery pharmaceutical glaucoma • Extending leadership in MIGS treatment class with therapy industry’s most comprehensive surgical offering • Solid cadence of new, market-expanding product int
Slide 27: 27 © 2017 Glaukos Corporation
27 © 2017 Glaukos Corporation 2